{"schema_version":"secwatch.filing_event.v1","accession":"0001510964-22-000040","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.974415+00:00","generated_at":"2026-06-25T14:41:03.125255+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CV Sciences Q1 revenue $4.4M (-8% YoY); operating loss narrows to $1.5M on ERC benefit","bullets":["Revenue $4.4M, down 8% from $4.8M in Q1 2021; units shipped up 3% offset by discounts and mix.","Operating loss narrowed to $1.5M from $3.1M in Q1 2021; included $2.0M employee retention credit.","Gross margin 26.0%, down from 32.4% in Q4 2021 sequentially; pressure from discounts/mix.","Negative adjusted EBITDA $2.5M vs $2.3M a year ago; cash rose to $2.4M from $1.4M.","Strategic review continues for possible merger/sale; launched new PlusCBD and OTC pain products."],"urls":{"canonical":"https://secwatch.observer/filing/0001510964-22-000040","json":"https://secwatch.observer/filing/0001510964-22-000040.json","markdown":"https://secwatch.observer/filing/0001510964-22-000040.md","text":"https://secwatch.observer/filing/0001510964-22-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000151096422000040/0001510964-22-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000151096422000040/cvsi-20220516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T14:41:03.125255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}